Lucid Diagnostics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LUCD | PAVM | EKF.L | BOUL.ST | TRIB | BMRA | |
|---|---|---|---|---|---|---|
| Market cap | 84.99M | 13.27M | 101.96M | 50.29M | 5.23M | 7.98M |
| P/E (TTM) | — | — | 23.8 | — | — | — |
| Forward P/E | -2.7 | -0.7 | 12.9 | 1.1 | -6.2 | 4.4 |
| Price/book | 7.8 | 0.3 | 1.5 | 0.3 | -0.1 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −62.48% | −82.77% | −6.40% | −86.51% | −77.91% | −34.11% |
| Today | +8.83% | −8.79% | +0.95% | +8.82% | −2.02% | +2.06% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All LUCD news ›Lucid Diagnostics announces 11,991‑patient EsoGuard study publication
Collection succeeded in 94.7 per cent of patients, but the retrospective analysis measures feasibility rather than comparative cancer outcomes. Cell collection succeeded in 94.7 per cent of patients as Lucid Diagnostics Inc. NASDAQLUCD…
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and... Lucid is now submitting Medicare claims and receiving payments at EsoGuard's…
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
/PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and... Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 29, 2026 /PRNewswire/ --…
Lucid Diagnostics (LUCD) and Its Competitors Critical Survey
Posted by Mitch Edgeman on Nov 2nd, 2026 Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Lucid Diagnostics…
Medicare Begins Reimbursing Lucid Diagnostics’ EsoGuard Test
Oct 23, 2026 | Company News, Molecular Diagnostics | Lucid Diagnostics Inc has begun receiving Medicare reimbursement for its EsoGuard Esophageal DNA Test at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test. The…
Lucid Diagnostics Receives Nasdaq Notice for Sub-$1 Bid Price, Faces Compliance Deadline
Kalkine Media On October 16, 2026, Lucid Diagnostics Inc. filed a Form 8-K revealing it received a Nasdaq deficiency notice dated October 12, 2026, due to its stock failing to maintain the required minimum closi
Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
TradingView Lucid Diagnostics Disclosed Failure to Satisfy a Continued Listing Rule or Standard On October 12, 2026, the company received a Nasdaq notice that its common stock failed to meet the $1.00 minimum bid pr
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com2
- clpmag.com1
- kalkinemedia.com1
- mugglehead.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.